Navigation Links
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
Date:10/9/2008

SKOKIE, Ill., Oct. 9 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced today that Robert J. De Vaere has joined the Company as executive vice president and chief financial officer.

"Bob is an experienced executive who brings more than 28 years of financial management experience to Horizon, including the last decade in healthcare with both public and private companies," said Timothy P. Walbert, president and chief executive officer. "During his career, Bob has been instrumental in numerous M&A transactions as well as an IPO and will be an important part of Horizon's future growth."

Mr. De Vaere's most recent position was as senior vice president, finance and administration and chief financial officer of IDM Pharma, Inc. (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Additionally, Mr. De Vaere served as vice president, finance and administration and chief financial officer of IDM Pharma from August 2005 to March 2006, and was vice president and chief financial officer of Epimmune from May 2000 until the business combination with IDM Pharma in August 2005.

Mr. De Vaere has also served as chief financial officer of Nexa Orthopedics, which was acquired by Tornier, Inc. and vice president of finance and administration and chief financial office of Vista Medical Technologies, Inc., a medical device company.

Earlier in his career, Mr. De Vaere held accounting, finance and administrative positions within the electronics and aerospace industries. Mr. De Vaere received a bachelor's degree from the University of California, Los Angeles.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
9. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
10. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Kablooe Design, a leading provider ... announced its official 25th anniversary of the business. “We have worked hard to build ... our customers for the privilege and honor of serving their product design and development ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... May 19, 2016 - I ... orale durante il 52 ° ...    - Le conclusioni dello studio indicano ... pazienti trattati, di cui il 90% presenta una d ... o più. Il settantadue per cento dei pazienti ha riscontrato ...
(Date:5/18/2016)... ... 18, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... assault kit processing to help them save time and reduce errors. , Sexual Assault ... be processed and victims informed of results. Due to a previous lack of tools, ...
Breaking Biology Technology:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
Breaking Biology News(10 mins):